| Predicate |
Object |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02P20-55
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C2601-14 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C231-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D209-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C269-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C271-56
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C269-04 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D209-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C271-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C231-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C271-56
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4045
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C269-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C269-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C237-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-27 |
| filingDate |
2021-05-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2022-05-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
2022-05-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CN-113233996-B |
| titleOfInvention |
Novel TRPV1 antagonistic/FAAH inhibition double-target drug, and preparation method and application thereof |
| abstract |
The invention discloses a novel TRPV1 antagonistic/FAAH inhibition double-target drug and a preparation method and application thereof, wherein the structural general formula of the TRPV1 antagonistic/FAAH inhibition double-target drug or pharmaceutically acceptable salt thereof is as follows: Ar 1 is substituted phenyl or aromatic heterocyclic radical; ar (Ar) 2 Is composed of X is N or O. The invention also relates to a preparation method of the compounds and a pharmaceutical preparation containing the compounds. The double-target analgesic designed and synthesized by the invention, which can inhibit FAAH and antagonize TRPV1 receptor, is expected to balance the biological activities to different targets, achieve excitation-inhibition balance, and can produce better analgesic effect and fewer adverse reactions at lower dosage. |
| priorityDate |
2021-05-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |